What happened with KYMR today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Kymera Therapeutics is developing oral small-molecule medicines, mainly for immune-related diseases. Its approach uses medicines to make cells break down selected disease-related proteins, known as targeted protein degradation. Its candidates are still in research or clinical development; none is approved for sale, and it has never earned drug-sales revenue.
Pharmaceutical partners pay Kymera for research and rights to drug programs. Sanofi has supplied most of its collaboration revenue. For the IRAK4 program outside oncology, Kymera handles discovery and early development, while Sanofi takes over later development, manufacturing and commercialization. The arrangement pays Kymera upfront and as specified milestones are reached, with royalties possible if products reach the market. Gilead has paid for an option on Kymera’s CDK2 cancer program; further payments depend on Gilead exercising that option and subsequent progress.
Kymera also funds its work through capital raising. It relies on outside organizations to conduct clinical trials and manufacture drug supplies. Drug sales require evidence of safety and effectiveness and regulatory approval, while collaboration income depends on partners continuing the programs.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Kymera depends on Sanofi to fund and take forward its IRAK4 protein-removing drugs: Sanofi supplied $33.6 million of Kymera’s $39.2 million collaboration revenue in 2025, while also pursuing competing STAT6 therapies. Watch Sanofi’s progress with KT-485/SAR447971, which it chose to advance into clinical testing after stopping KT-474.
Nurix Therapeutics and Kymera both depend on drugmakers paying for research into medicines that remove disease-related proteins, with Sanofi and Gilead funding both companies. Nurix’s collaboration revenue from those two partners offers a comparison for Kymera’s reliance on research payments rather than product sales.
Monte Rosa Therapeutics shares Kymera’s push to treat immune diseases by removing disease-related proteins, and their CDK2-related cancer programs overlap. Monte Rosa’s licensing of its VAV1 drugs, including MRT-6160, to Novartis offers a concrete comparison for drugmakers’ willingness to pay for this approach.
Odyssey Therapeutics could compete with Kymera by blocking IRF5 and IRAK4 rather than removing those same inflammatory signaling proteins. Watch its IRF5 work with Terray Therapeutics and its preclinical IRAK4 program; Odyssey has no approved products or product-sale revenue.
Enanta Pharmaceuticals could compete directly with Kymera for atopic dermatitis treatment: Enanta is developing an oral drug that blocks STAT6, while Kymera’s oral drug removes that protein.
Arvinas provides a test of the drug approach behind Kymera: both develop small molecules that remove disease-causing proteins, so evidence that they work matters to both despite different lead indications. Watch clinical evidence for Arvinas’s degraders, including vepdegestrant, which it develops with Pfizer under shared development costs and potential milestone payments.
C4 Therapeutics and Kymera both develop oral drugs that remove disease-related proteins and receive payments from drugmakers for discovery programs. C4’s funded research with Merck KGaA—and its discovery milestone earned in April 2025—offers a comparison for progress toward payments under Kymera’s licensing deals.
Gilead Sciences pays Kymera to discover CDK2 protein-removing drugs and can choose to license them for further development, but it also pursues competing STAT6 therapies. Watch whether Gilead exercises that option: doing so would bring Kymera a $45 million payment and eligibility for further milestones and sales royalties.
ImageneBio could compete with Kymera for systemic treatment of atopic dermatitis, using an antibody that blocks OX40 signaling rather than Kymera’s oral STAT6 degrader. Watch IMG-007’s clinical results and dosing schedule: ImageneBio is exploring whether its long half-life allows less frequent dosing, and it has no product-sale revenue.
Oruka Therapeutics could compete with Kymera’s partnered IRAK4 program in hidradenitis suppurativa: its ORKA-002 targets a different inflammatory pathway in the same disease.
Sanofi earningsSNY
Sanofi’s report gives readers a chance to watch whether it continues advancing KT-485, the IRAK4 program linked to Kymera, and what that means for the collaboration.
Watch for updates on Sanofi’s progress with and commitment to KT-485. Continued advancement would show Sanofi is still devoting resources to research linked to Kymera; a pause or no clear progress would make the collaboration’s timing and potential value harder to assess. Sanofi’s update is not a report of Kymera’s own clinical results or revenue.
Kymera Therapeutics, Inc. earningsThis company
Kymera has no product sales and relies on drugmakers’ research payments, so its report shows how collaboration revenue compares with the cost of developing its medicines.
Read collaboration revenue alongside operating expenses, and note which partnerships contribute the revenue. Rising collaboration revenue with controlled expense growth means research payments are covering more development costs; falling revenue as expenses rise means Kymera must use more of its cash to advance programs. The question is whether partner funding keeps pace with development costs—not whether one quarter’s revenue represents drug sales.
Arvinas, Inc earningsARVN
Arvinas’s report may show clinical evidence for its protein-degrading drugs, offering a read-through on the approach Kymera also uses.
Look for clinical data on Arvinas’s degraders, including updates on vepdegestrant, which it develops with Pfizer. Evidence of activity in patients would strengthen the case that this protein-degradation approach can work in the clinic; disappointing or inconclusive data would underline that early findings may not translate. Arvinas’s different drugs and indications cannot prove Kymera’s programs work.
Enanta Pharmaceuticals, Inc earningsENTA
Enanta’s report may show progress for its oral STAT6 blocker in atopic dermatitis, where it competes with Kymera’s oral STAT6 degrader.
Watch clinical progress for Enanta’s oral STAT6 blocker in atopic dermatitis. Positive evidence would show another oral STAT6 treatment advancing and raise the prospect of more direct competition for patients and market access; weak progress would mean less immediate competitive pressure from this program. Blocking STAT6 and degrading it are different approaches, so Enanta’s results cannot show whether Kymera’s drug works.
